Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ERIC ANTHONY WANG

Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology

NPI
1356335988
CMS profile
60815
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$18,868.41

66 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Terumo Medical Corporation $9,898.51 15
Sirtex Medical Inc $5,706.64 12
Penumbra, Inc. $2,415.43 11
Imperative Care, Inc $336.16 9
Medtronic, Inc. $307.00 11
Boston Scientific Corporation $86.10 1
TriSalus Life Sciences, Inc. $54.01 3
Balt USA, LLC $29.78 2
Cook Medical LLC $20.43 1
Abbott Laboratories $14.35 1

Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ERIC ANTHONY WANG

NPI 1356335988 · CMS profile ID 60815

Allopathic & Osteopathic Physicians / Radiology / Diagnostic Radiology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356335988?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ERIC ANTHONY WANG, NPI 1356335988, CMS profile ID 60815. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356335988?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ERIC ANTHONY WANG, NPI 1356335988, CMS profile ID 60815. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356335988?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ERIC ANTHONY WANG, NPI 1356335988, CMS profile ID 60815, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1356335988?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

66 matching records · $18,868.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 66 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–66 of 66.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boston Scientific Corporation $86.1006/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022031627 CMS
Penumbra, Inc. $141.6906/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987669471 CMS
Medtronic, Inc. $28.5106/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019567417 CMS
Sirtex Medical Inc $149.6505/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032410699 CMS
Imperative Care, Inc $50.5605/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1047391405 CMS
Medtronic, Inc. $32.9705/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019567411 CMS
Medtronic, Inc. $27.7805/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019567405 CMS
TriSalus Life Sciences, Inc. $19.3404/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055085561 CMS
Cook Medical LLC $20.4304/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022753571 CMS
Medtronic, Inc. $31.5604/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019567399 CMS
Medtronic, Inc. $28.5203/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019567393 CMS
Medtronic, Inc. $22.0402/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019567387 CMS
Penumbra, Inc. $124.5902/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987669469 CMS
TriSalus Life Sciences, Inc. $17.6702/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055085553 CMS
Imperative Care, Inc $143.6402/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1047391399 CMS
Imperative Care, Inc $13.8401/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1047391393 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $19,385.55 63
PY2020 $32,564.66 53
PY2021 $30,341.52 85
PY2022 $25,112.64 71
PY2023 $18,868.41 66
PY2024 $11,024.34 51
PY2025 $56,833.54 112

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Recipient $44,229.10 20
PY2024 Principal investigator $384,676.44 115

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

135 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient ABK Biomedical USA, Inc. $6,000.00 12/22/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095148
Recipient ABK Biomedical USA, Inc. $2,228.41 12/22/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095150
Recipient ABK Biomedical USA, Inc. $500.00 12/19/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095146
Recipient ABK Biomedical USA, Inc. $5,500.00 12/13/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095142
Recipient ABK Biomedical USA, Inc. $1,733.10 12/13/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095144
Principal investigator 1 ABK Biomedical USA, Inc. $11,583.14 12/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101477
Principal investigator 1 ABK Biomedical USA, Inc. $4,296.65 12/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101479
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 12/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101481
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 12/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101483
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 12/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101485
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 12/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101487
Recipient ABK Biomedical USA, Inc. $1,986.32 11/28/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095138
Recipient ABK Biomedical USA, Inc. $8,500.00 11/28/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095140
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 11/05/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101463
Principal investigator 1 ABK Biomedical USA, Inc. $6,280.09 11/05/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101465
Principal investigator 1 ABK Biomedical USA, Inc. $4,296.65 11/05/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101467
Principal investigator 1 ABK Biomedical USA, Inc. $309.29 11/05/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101469
Principal investigator 1 ABK Biomedical USA, Inc. $240.35 11/05/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101471
Principal investigator 1 ABK Biomedical USA, Inc. $240.35 11/05/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101473
Principal investigator 1 ABK Biomedical USA, Inc. $240.35 11/05/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101475
Recipient ABK Biomedical USA, Inc. $96.00 10/21/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095112
Recipient ABK Biomedical USA, Inc. $2,000.00 10/08/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095136
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101409
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101411
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101413
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101415
Principal investigator 1 ABK Biomedical USA, Inc. $11,583.14 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101417
Principal investigator 1 ABK Biomedical USA, Inc. $11,583.14 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101419
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101421
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101423
Principal investigator 1 ABK Biomedical USA, Inc. $6,280.09 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101425
Principal investigator 1 ABK Biomedical USA, Inc. $4,296.65 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101427
Principal investigator 1 ABK Biomedical USA, Inc. $1,652.84 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101429
Principal investigator 1 ABK Biomedical USA, Inc. $1,652.84 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101431
Principal investigator 1 ABK Biomedical USA, Inc. $4,330.80 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101433
Principal investigator 1 ABK Biomedical USA, Inc. $4,330.80 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101435
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101437
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101439
Principal investigator 1 ABK Biomedical USA, Inc. $4,296.65 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101441
Principal investigator 1 ABK Biomedical USA, Inc. $4,296.65 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101443
Principal investigator 1 ABK Biomedical USA, Inc. $309.29 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101445
Principal investigator 1 ABK Biomedical USA, Inc. $309.29 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101447
Principal investigator 1 ABK Biomedical USA, Inc. $110.22 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101449
Principal investigator 1 ABK Biomedical USA, Inc. $110.22 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101451
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101453
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101455
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101457
Principal investigator 1 ABK Biomedical USA, Inc. $240.35 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101459
Principal investigator 1 ABK Biomedical USA, Inc. $240.35 10/08/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101461
Recipient ABK Biomedical USA, Inc. $105.20 10/05/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095114
Recipient ABK Biomedical USA, Inc. $105.32 10/05/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095116
Recipient ABK Biomedical USA, Inc. $158.13 10/05/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095118
Recipient ABK Biomedical USA, Inc. $516.55 10/05/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095122
Recipient ABK Biomedical USA, Inc. $526.96 10/05/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095124
Recipient ABK Biomedical USA, Inc. $886.18 10/05/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095126
Recipient ABK Biomedical USA, Inc. $253.64 10/04/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095120
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101259
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101261
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101263
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101265
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101267
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101269
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101271
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101273
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101275
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101277
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101279
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101281
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101283
Principal investigator 1 ABK Biomedical USA, Inc. $11,583.14 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101285
Principal investigator 1 ABK Biomedical USA, Inc. $11,583.14 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101287
Principal investigator 1 ABK Biomedical USA, Inc. $11,583.14 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101289
Principal investigator 1 ABK Biomedical USA, Inc. $11,583.14 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101291
Principal investigator 1 ABK Biomedical USA, Inc. $11,583.14 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101293
Principal investigator 1 ABK Biomedical USA, Inc. $11,583.14 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101295
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101297
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101299
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101301
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101303
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101305
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101307
Principal investigator 1 ABK Biomedical USA, Inc. $6,280.09 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101309
Principal investigator 1 ABK Biomedical USA, Inc. $6,280.09 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101311
Principal investigator 1 ABK Biomedical USA, Inc. $1,652.84 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101313
Principal investigator 1 ABK Biomedical USA, Inc. $1,652.84 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101315
Principal investigator 1 ABK Biomedical USA, Inc. $1,652.84 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101317
Principal investigator 1 ABK Biomedical USA, Inc. $1,652.84 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101319
Principal investigator 1 ABK Biomedical USA, Inc. $1,652.84 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101321
Principal investigator 1 ABK Biomedical USA, Inc. $1,652.84 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101323
Principal investigator 1 ABK Biomedical USA, Inc. $4,330.80 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101325
Principal investigator 1 ABK Biomedical USA, Inc. $4,330.80 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101327
Principal investigator 1 ABK Biomedical USA, Inc. $4,330.80 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101329
Principal investigator 1 ABK Biomedical USA, Inc. $4,330.80 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101331
Principal investigator 1 ABK Biomedical USA, Inc. $4,330.80 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101333
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101335
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101337
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101339
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101341
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101343
Principal investigator 1 ABK Biomedical USA, Inc. $307.40 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101345
Principal investigator 1 ABK Biomedical USA, Inc. $4,296.65 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101347
Principal investigator 1 ABK Biomedical USA, Inc. $4,296.65 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101349
Principal investigator 1 ABK Biomedical USA, Inc. $4,296.65 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101351
Principal investigator 1 ABK Biomedical USA, Inc. $4,296.65 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101353
Principal investigator 1 ABK Biomedical USA, Inc. $309.29 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101355
Principal investigator 1 ABK Biomedical USA, Inc. $309.29 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101357
Principal investigator 1 ABK Biomedical USA, Inc. $309.29 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101359
Principal investigator 1 ABK Biomedical USA, Inc. $309.29 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101361
Principal investigator 1 ABK Biomedical USA, Inc. $309.29 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101363
Principal investigator 1 ABK Biomedical USA, Inc. $309.29 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101365
Principal investigator 1 ABK Biomedical USA, Inc. $309.29 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101367
Principal investigator 1 ABK Biomedical USA, Inc. $110.22 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101369
Principal investigator 1 ABK Biomedical USA, Inc. $110.22 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101371
Principal investigator 1 ABK Biomedical USA, Inc. $110.22 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101373
Principal investigator 1 ABK Biomedical USA, Inc. $110.22 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101375
Principal investigator 1 ABK Biomedical USA, Inc. $110.22 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101377
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101379
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101381
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101383
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101385
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101387
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101389
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101391
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101393
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101395
Principal investigator 1 ABK Biomedical USA, Inc. $9,198.83 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101397
Principal investigator 1 ABK Biomedical USA, Inc. $240.35 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101399
Principal investigator 1 ABK Biomedical USA, Inc. $240.35 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101401
Principal investigator 1 ABK Biomedical USA, Inc. $240.35 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101403
Principal investigator 1 ABK Biomedical USA, Inc. $240.35 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101405
Principal investigator 1 ABK Biomedical USA, Inc. $240.35 09/10/2024 Non-covered Recipient Entity
CHARLOTTE RADIOLOGY, PA
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155101407
Recipient ABK Biomedical USA, Inc. $1,051.28 09/04/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095132
Recipient ABK Biomedical USA, Inc. $5,500.00 09/04/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095134
Recipient ABK Biomedical USA, Inc. $1,082.01 07/09/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095128
Recipient ABK Biomedical USA, Inc. $5,500.00 07/09/2024 Covered Recipient Physician Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) No dispute reported 06/30/2026 1155095130